Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a buy rating to a strong-buy rating in a report issued on Saturday morning.

Several other analysts also recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, January 21st. Scotiabank raised their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research report on Thursday, January 29th. The Goldman Sachs Group boosted their price objective on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Piper Sandler increased their target price on Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the stock an “overweight” rating in a research note on Monday, December 22nd. Finally, Bank of America lifted their price target on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and a consensus price target of $36.00.

Teva Pharmaceutical Industries Stock Up 4.3%

Shares of TEVA stock opened at $35.56 on Friday. The company has a debt-to-equity ratio of 2.31, a quick ratio of 0.82 and a current ratio of 1.11. The firm’s 50-day moving average is $30.71 and its 200-day moving average is $23.39. The stock has a market cap of $40.78 billion, a price-to-earnings ratio of 29.63, a PEG ratio of 1.94 and a beta of 0.70. Teva Pharmaceutical Industries has a 52-week low of $12.47 and a 52-week high of $35.69.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 48.20% and a net margin of 8.16%.The company had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same period last year, the firm posted $0.71 earnings per share. The business’s revenue was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Sell-side analysts predict that Teva Pharmaceutical Industries will post 2.5 EPS for the current year.

Insider Buying and Selling

In related news, VP Richard Daniell sold 115,468 shares of the firm’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total value of $3,311,622.24. Following the transaction, the vice president owned 48,384 shares in the company, valued at approximately $1,387,653.12. This trade represents a 70.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mark Sabag sold 216,892 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the completion of the transaction, the insider directly owned 52,828 shares in the company, valued at approximately $1,517,748.44. This represents a 80.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 622,060 shares of company stock valued at $17,076,965. 0.55% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TEVA. Vontobel Holding Ltd. boosted its holdings in shares of Teva Pharmaceutical Industries by 5.5% during the 2nd quarter. Vontobel Holding Ltd. now owns 719,676 shares of the company’s stock worth $12,062,000 after buying an additional 37,455 shares in the last quarter. Phoenix Financial Ltd. increased its stake in Teva Pharmaceutical Industries by 9.4% during the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after purchasing an additional 3,533,800 shares in the last quarter. Oak Harvest Investment Services acquired a new position in Teva Pharmaceutical Industries during the third quarter worth $1,010,000. Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 12.9% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock valued at $761,455,000 after buying an additional 4,306,363 shares in the last quarter. Finally, Teacher Retirement System of Texas lifted its stake in shares of Teva Pharmaceutical Industries by 11.2% in the third quarter. Teacher Retirement System of Texas now owns 697,574 shares of the company’s stock valued at $14,091,000 after buying an additional 69,994 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.